FDA Clears Calypso’s ‘GPS for the Body’ in Prostatectomy Patients

The FDA has cleared a new indication for Calypso Medical’s implantable Beacon electromagnetic transponders in external beam radiation therapy for recurrent prostate cancer.

Known as “GPS for the body,” the system uses transponders to set up and continuously track the position of targeted tissue during radiation treatment.

If a tumor site moves outside of acceptable limits, the clinician can adapt the therapy to ensure the proper delivery of treatment prescribed to the cancerous tissue while avoiding adjacent healthy organs, the company said. Previously, this technology was cleared solely for use in patients with intact prostates.